TL13-112 is a degrader of anaplastic lymphoma kinase (ALK) with an IC50 of 0.60 nM. It demonstrates anti-proliferative activity in non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL) cell lines.

TL13-112 is a degrader of anaplastic lymphoma kinase (ALK) with an IC50 of 0.60 nM. It demonstrates anti-proliferative activity in non-small-cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL) cell lines.

Fulzerasib (IBI351, GFH925) is an irreversible small molecule inhibitor for KRAS G12C mutation blocking KRAS pathway signaling pERK with an IC50 of 37 nM. It demonstrates potent anti-tumor activity in multiple KRAS G12C-mutant tumor models including human pancreatic cancer, human lung adenocarcinoma, colorectal adenocarcinoma, and lung cancer models.

Fulzerasib (IBI351, GFH925) is an irreversible small molecule inhibitor for KRAS G12C mutation blocking KRAS pathway signaling pERK with an IC50 of 37 nM. It demonstrates potent anti-tumor activity in multiple KRAS G12C-mutant tumor models including human pancreatic cancer, human lung adenocarcinoma, colorectal adenocarcinoma, and lung cancer models.

Fulzerasib (IBI351, GFH925) is an irreversible small molecule inhibitor for KRAS G12C mutation blocking KRAS pathway signaling pERK with an IC50 of 37 nM. It demonstrates potent anti-tumor activity in multiple KRAS G12C-mutant tumor models including human pancreatic cancer, human lung adenocarcinoma, colorectal adenocarcinoma, and lung cancer models.

Fulzerasib (IBI351, GFH925) is an irreversible small molecule inhibitor for KRAS G12C mutation blocking KRAS pathway signaling pERK with an IC50 of 37 nM. It demonstrates potent anti-tumor activity in multiple KRAS G12C-mutant tumor models including human pancreatic cancer, human lung adenocarcinoma, colorectal adenocarcinoma, and lung cancer models.

Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models.

Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models.

Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models.

Palazestrant(OP-1250) is an orally bioavailable complete antagonist of estrogen receptor (ER) that blocks ER activity. It exhibits antiproliferative and antitumor activity in ER-positive (ER+) breast cancer models.